Marshall Wace North America’s Intellia Therapeutics NTLA Stock Holding History

Marshall Wace North America’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-185,147	Closed	-$30M	–	1623
2021 Q2	$30M	Sell	185,147 -41,456	-18%	-$3.23M	0.12%	171
2021 Q1	$18.2M	Sell	226,603 -253,475	-53%	-$17M	0.08%	267
2020 Q4	$26.1M	Buy	+480,078	New	+$17.4M	0.12%	202
2020 Q2	–	Sell	-5,771	Closed	-$71K	–	1371
2020 Q1	$71K	Buy	+5,771	New	+$77.7K	﹤0.01%	1041

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Marshall Wace North America's NTLA Position: Q3 2021 in Review

Marshall Wace North America sold out of Intellia Therapeutics (NTLA) in Q3 2021, closing a stake of 185,147 shares — an estimated $30M sold.

Marshall Wace North America first reported a position in NTLA in Q1 2020 and held it in 4 quarters. The position peaked at $30M in Q2 2021. 365 funds tracked by Wall St. Rank hold NTLA as of Q3 2021.

Marshall Wace North America reported no remaining Intellia Therapeutics position as of Q3 2021 after selling out during the quarter.
Marshall Wace North America sold 185,147 Intellia Therapeutics shares in Q3 2021, an estimated $30M.
Marshall Wace North America first reported a position in Intellia Therapeutics in Q1 2020 and held it in 4 quarters.
Marshall Wace North America's Intellia Therapeutics position peaked at $30M in Q2 2021.
365 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.